Chlorambucil may be a more reasonable choice f... - CLL Support

CLL Support

23,335 members40,042 posts

Chlorambucil may be a more reasonable choice for elderly CLL patients than fludarabine.

AussieNeil profile image
AussieNeilPartnerAdministrator
0 Replies

A recent study published in the Journal of Clinical Oncology, which includes among its authors Drs Kanti Rai and John Byrd, found chlorambucil is an acceptable treatment for many older patients with CLL and suggest rituximab is beneficial regardless of age:

jco.ascopubs.org/content/31...

"Results: A total of 663 patients were evaluated for response, progression-free survival (PFS), and overall survival (OS) by age group. Interaction effects of fludarabine versus chlorambucil by age group showed that among patients younger than 70 years, PFS and OS was improved with fludarabine over chlorambucil , but not in older adults. In contrast, Fludarabine/Rituximab (FR) improved outcomes relative to fludarabine, irrespective of age. Alemtuzumab consolidation did not provide benefit over similar regimens without alemtuzumab, irrespective of age."

Neil

Written by
AussieNeil profile image
AussieNeil
Partner
To view profiles and participate in discussions please or .
Read more about...

Not what you're looking for?

You may also like...

Health Canada approves Ibrutinib plus Rituximab for First Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Good News for our untreated Canadian members! This latest approval is based on...
AussieNeil profile image
Partner

GAZYVA® (Obinutuzumab) gains TGA approval for 1st line treatment of CLL in combination with Chlorambucil in Australia

GAZYVA, a new anti-CD20 monoclonal antibody, is now Therapeutic Goods Administration (TGA)...
AussieNeil profile image
Partner

From the CLL14 Study: Venetoclax Plus Obinutuzumab Prolongs Progression Free Survival, Not Overall Survival , in CLL

These results, from the CLL14 study (ClinicalTrials.gov Identifier: NCT02242942), were presented at...
Jm954 profile image
Administrator

Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with CLL

This is an abstract from the Lancet article. There's a fair bit of detail missing regarding the...
Jm954 profile image
Administrator

Late breaking CLL abstract at ASH 2018 (FCR vs IR for untreated younger patients)

https://ash.confex.com/ash/2018/webprogram/Paper120779.html CONCLUSIONS: The combination of...
avzuclav profile image